NEws & EveNTS
|
Sustained Donor Chimerism and Rapid Immune Cell Reconstitution With a Low Probability of GVHD Following Familial Haploidentical (FHI) CD34 Enriched Stem Cell Transplantation with PBMNC AddBack in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359) 
Click here to view PDF
|
|
Dr. Cairo’s Recent Interview with HemOnc Today from the American Society of Hematology (ASH) 2018 meeting
|
|
|
Sickle Cell Warriors
Maria Fareri Children's Hospital / Westchest Medical Center
05/23/19
05/23/19
|
Dr Mitchell Cairo featured at Docwire Conference: Stem Cell Transplant Outcome in Sickle Cell Disease
|
|
|
Docwire
01/11/19 Mitchell S. Cairo, M.D., professor of pediatrics, division of pediatric hematology, oncology and stem cell transplantation, and professor of medicine, pathology, microbiology and immunology, and cell biology and anatomy Read full article here Novel Therapies Offer Hope in Sickle Cell Disease
Medpage Today 12/2/2018 Mitchell S. Cairo, M.D., professor of pediatrics, division of pediatric hematology, oncology and stem cell transplantation, and professor of medicine, pathology, microbiology and immunology, and cell biology and anatomy Read full article here Familial stem cell transplant improves outcomes in high-risk sickle cell disease
Healio 12/1/2018 Mitchell S. Cairo, M.D., professor of pediatrics, division of pediatric hematology, oncology and stem cell transplantation, and professor of medicine, pathology, microbiology and immunology, and cell biology and anatomy Read full article here Studies Show Improved Sickle Cell Disease Outcomes Worldwide
ABC 8 12/1/2018 Mitchell S. Cairo, M.D., professor of pediatrics, division of pediatric hematology, oncology and stem cell transplantation, and professor of medicine, pathology, microbiology and immunology, and cell biology and anatomy Read full article here |
ABSTRACTS
Braniecki, S., Moore, T.B., Talano, J.A., Shi, Q., Flower, A., Panarella, A., Fabricatore, S., Morris, E., Milner, J., McKinstry, R., Shenoy, S., and Cairo, M.S. Stable to improved neurocognitive outcomes in children, adolescents & young adults with high-risk sickle cell disease (SCD) who have undergone familial haploidentical transplantation: A prospective study from pre HSCT perior to 2 years post HSCT (IND 14359). Submitted, Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood & Marrow Transplant Research (CIBMTR), 2019. Presented, Feb. 23, 2020, #86.
Chu, Y., Talano, J.A., Baxter-Lowe, L.A., Morris, E., Mahanti, H., Ayello, J., Keever-Taylor, C.A., Johnson, B.D., Weinberg, R.S., Shi, Q., Moore,T.B., Fabricatore, S., Grossman, B., van de Ven, C., Shenoy, S., and Cairo, M.S. Sustained donor chimerism and rapid immune cell reconstitution with a low probability of GVHD following familial haploidentical (FHI) CD34 enriched stem cell transplantation with PBMNC addback in patients with high risk sickle cell disease (SCD) (IND 14359). Submitted, Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood & Marrow Transplant Research (CIBMTR), 2019. Presented, Feb. 22, 2020, #463.
Chu, Y., Talano, J.A., Baxter-Lowe, L.A., Morris, E., Mahanti, H., Ayello, J., Keever-Taylor, C., Weinberg, R.S., Shi, Q., Moore, T.B., Fabricatore, S., Grossman, B., van de ven, C., Shenoy, S., Cairo, M. Sustained donor chimerism and rapid immune cell reconstitution with a low probability of GVHD following familial haploidentical (FHI) CD34 enriched stem cell transplantation with PBMNC addback in patients with high risk sickle cell disease (SCD). Presented, 2ndInternational Symposium on Biology, Prevention, and Treatment of Toxicities after Transplantation and Cellular Therapy, 2019.
Chu, Y., Talano, J-A., Baxter-Lowe, L.A., Morris, E., Mahanti, H., Ayello, J., Keever-Taylor, C., Weinberg, R., Shi, Q., Moore, T.B., Fabricatore, S., Grossman, B., van de Ven, C., Shenoy, S., and Cairo, M.S. Sustained donor chimerism and rapid immune cell reconstitution following familial haploidentical (FHI) CD34 enriched stem cell transplantation with PB-MNC addback in patients with high risk sickle cell disease (SCD) (IND 14359). Presented, American Society of Hematology (ASH), December 2019, #126757; Blood (2019) 134:Supplement_1:1990. Doi: 10.1182/blood-2019-126757
Talano, J-A., Moore, T.B., Parsons, S.K., Dozor, A.J., Friedman, D., Shi, Q., Braniecki, S., Weinberg, R.S., Morris, E., Fabricatore, S., Ayello, J., Baxter-Lowe, L.A., Cooke, K., Duncan, C., Guillerman, R.P., Mahanti, H., van de Ven, C., and Cairo, M.S. The safety and efficacy of prophylactic defibrotide administration in children, adolescents and young adults (CAYA) with sickle cell disease following myeloablative conditioning (MAC) and familial haploidentical (FHI) stem cell transplantation utilizing CD34 enrichment and T-cell (CD3) addback (IND 127812). Presented, Pediatric Blood and Marrow Transplant Consortium (PBMTC), May 2019, #1016.
Braniecki, S., Piela, G., Cairo, M.S., Dozor, A., Friedman, D., Moorthy, C., Ayello, J., Semidei-Pomales, M., Flower, A., Chu, Y., Morris, E., Mahanti, H., Fabricatore, S., Klejmont, L., and van de Ven, C. “Neurocognitive outcomes in children, adolescents and young adults with high-risk sickle cell disease (SCD) who have undgeronge familial haploidentical stem cell transplantation: a prospective study from pre-transplant period to 2 years post transplantation. Presented, Society of Pediatric Psychology Annual Conference (SPPAC), April 2019.
Long, B.G., Flower, A., Fabricatore, S., Morris, E., Mahanti, H., Shi, Q., Keever-Taylor, C.A., Weinberg, R.S., Grossman, B., Talano, J-A.M., Shenoy, S., Moore, T.B., Ayello, J., Semidei-Pomales, M., van de Ven, C., and Cairo, M.S. Assessment of safety and efficacy of PBSC mobilization with G-CSF and CD34+ enrichment and pbmnc (CD3+) addback in familial haploidentical (FHI) adult donors with sickle cell disease trait (SCDT) prior to allogeneic HSCT of high-risk SCD patients. Presented, Association of Blood and Marrow Transplantation (ASBMT), 2018. Biology of Blood and Marrow Transplantation, March 2019; S1, 25(3):S310, #457.
Cairo, M.S., Parsons, S.K., Braniecki, S., Talano, J-A., Moore, T.B., Shi, Q., Keever-Taylor, C., Weinberg, R.S., Grossman, B., Dozor, A.J., Friedman, D., McKinstry, R.C., Verbsky, J., Moorthy, C.R., Weidner, R.A., Rodday, A.M., Ayello, J., Semidei-Pomales, M., Flower, A., Chu, Y., Morris, E., Mahanti, H., Fabricatore, S., Militano, O., Klejmont, L., van de Ven, C., Baxter-Lowe, L.A., Vichinsky, E., Walters, M.C., and Shenoy, S. Significantly improved long term health related quality of life (HRQL) and neurocognition following familial haploidentical stem cell transplantation (HISCT) utilizing CD34 enrichment and mononuclear (CD3) addback in high risk patients with sickle cell disease (SCD). Presented, American Society of Hematology (ASH). Blood 2018 Dec; 132:162. Doi: https://doi.org/10.1182/blood-2018-162
Cairo, M.S., Talano, J-A., Moore, T.B., Keever-Taylor, C., Shenoy, S., Walters, M.C., Parsons, S.K., Dozor, A.J., Friedman, D., Shi, Q., Braniecki, S., Grossman, B., Weinberg, R.S., Vichinsky, E., Chu, Y., Morris, E., Fabricatore, S., Ayello, J., and Baxter-Lowe, L.A. Final results following familial haploidentical (FHI) CD34 enriched and T-cell (CD3) addback allogeneic stem cell transplantation in patients with high-risk sickle cell disease (IND 14359). Presented, European Society for Blood and Marrow Transplantation (EBMT), Mar 2018. #A-947-0026-00477
Chu, Y., Verbsky, J., Talano, J-A., Morris, E., Ayello, J., Keever-Taylor, C., Baxter-Lowe, L.A., Weinberg, R., Semidei-Pomales, M., Shi, Q., Moore, T.B., Fabricatore, S., Grossman, B., Shenoy, S., and Cairo, M.S. Immune reconstitution in children and adolescents with high risk sickle cell disease (SCD) after familial haploidentical (FHI) allogeneic stem cell transplantation (AlloSCT) utilizing CD34 enrichment and PB MNC addback (IND 14359). Presented, Association of Blood and Marrow Transplantation (ASBMT), 2018, #523. Biology of Blood and Marrow Transplantation, March 2018; 24(3):S361.
Long, B., Fabricatore, S., Flower, A., Morris, E., Mahanti, H., Shi, Q., Keever-Taylor, C., Weinberg, R.S., Grossman, B., Talano, J-A., Shenoy, S., Moore, T.B., Ayello, J., Semidei-Pomales, M., van de Ven, C., and Cairo, M.S. Assessment of safety and efficacy of PBSC mobilization with G-CSF and CD34+ enrichment and PBMNC (CD3+) addback in familial haploidentical (FHI) adult donors with sickle cell disease trait (SCDT) prior to allogeneic HSCT of high-risk SCD patients. Presented, Association of Blood and Marrow Transplantation (ASBMT), 2018, #210. Biology of Blood and Marrow Transplantation, March 2018; 24(3):S162.
Flower, A., Talano, J., Moore, T., Shenoy, S., Broglie, L., Mahanti, H., Morris, E., Fabricatore, S., Dozor, A., and Cairo, M.S. Stable pulmonary function after myeloimmunosuppressive conditioning (MIC) and familial haploidentical (FHI) transplantation utilizing CD34+ enrichment and PBMC (CD3) add back in children and young adults with high risk (HR) sickle cell disease (SCD). Presented, Association of Blood and Marrow Transplantation (ASBMT), 2018, #300. Biology of Blood and Marrow Transplantation, March 2018; 24(3):S222.
Talano, J-A.T., Moore, T.B.M., Keever-Taylor, C.A., Shenoy, S., Walters, M.C., Parsons, S.K., Dozor, A.J., Friedman, D., Shi, Q., Braniecki, S., Grossman, B.J., Weinberg, R.S., Vichinsky, E., Chu, Y., Morris, E., Fabricatore, S., Ayello, J., Baxter-Lowe, L.A., and Cairo, M.S. Promising results at 1 year follow-up following familial haploidentical (FHI) T-cell depleted (TCD) with CD34 enrichment and T-cell (CD3) addback allogeneic stem cell transplantation in patients with high-risk sickle cell disease (SCD) (IND 14359). Presented, American Society of Hematology (ASH), Dec 2017; Blood 2017 130 (Suppl 1):4602.
Braniecki, S., Talano, J-A., Moore, T.B., Weinberg, R., Keever-Taylor, C., Grossman, B., Baxter-Lowe, L.A., Parsons, S., Morris, E., Fabricatore, S., Ayello, J., Semidei-Pomales, M., van de Ven, C., Abikoff, C., Shenoy, S., McKinstry, R., and Cairo, M.S. Neurocognitive and neurological outcomes in children, Adolescents and adults with high risk sickle cell disease (SCD) who have undergone familial haploidentical (FHI) allogeneic stem cell transplantation (AlloSCT) utiliziing CD34 enrichment and T cell addback following myeloimmunoablative conditioning (MIC). Presented, Pediatric Blood and Marrow Transplantation (PBMTC), Apr 2017; Pediatric Blood & Cancer; 2017: e26591, #1022.
Chu, Y., Talano, J-A., Baxter-Lowe, L.A., Morris, E., Mahanti, H., Ayello, J., Keever-Taylor, C., Weinberg, R., Shi, Q., Moore, T.B., Fabricatore, S., Grossman, B., van de Ven, C., Shenoy, S., and Cairo, M.S. Sustained donor chimerism and rapid immune cell reconstitution following familial haploidentical (FHI) CD34 enriched stem cell transplantation with PB-MNC addback in patients with high risk sickle cell disease (SCD) (IND 14359). Presented, American Society of Hematology (ASH), December 2019, #126757; Blood (2019) 134:Supplement_1:1990. Doi: 10.1182/blood-2019-126757
Broglie, L., Talano, J., Moore, T., Shenoy, S., Mahanti, H., Morris, E., Horowitz, T., Fabricatore, S., Abikoff, C., Dozor, A., and Cairo, M.S. Stabilization of pulmonary function in pediatric and young adult sickle cell disease recipients undergoing myelo-immunesuppressive (MIC) and familial haploidentical (FHI) transplantation enriched CD34 selection and T-cell add-back. Presented, Pediatric Blood and Marrow Transplantation (PBMTC), Apr 2017; Pediatric Blood & Cancer; 2017: e26591, #1017.
Cairo, M.S., Talano, J-A., Moore, T.B., Baxter-Lowe, L.A., Keever-Taylor, C., Grossman, B., Weinberg, R., Morris, E., Shi, Q., and Shenoy, S. The safety and efficacy of familial haploidentical (FHI) stem cell transplantation utilizing CD34 enrichment and CD3 addback in patients with high risk sickle cell disease (SCD) (IND 14359). Presented, European Society for Blood and Marrow Transplantation (EBMT), Mar 2017, #B289.
Talano, J-A., Abikoff, C., Keever-Taylor, C., Walters, M.C., Shenoy, S., Moore, T.B., Parsons, S.K., Dozor, A.J., Friedman, D., Shi, Q., Braniecki, S., Grossman, B., Weinberg, R.S., Morris, E., Brand, P., Fabricatore, S., Ayello, J., Semidei-Pomales, M., Baxter-Lowe, L.A., and Cairo, M.S. Familial haploidentical (FHI) T-cell depleted (TCD) with T-cell addback stem cell transplantation for patients with high-risk sickle cell disease. Presented, American Society of Blood and Marrow Transplantation, Feb 2017; Biology of Blood and Marrow Transplantation, March 2017; 23(3):S246-S247.
Parsons, S.K., Rodday, A.M., Weidner, R.A., Morris, E., Moore, T.B., Shenoy, S., Talano, J-A., Minzer, S., Fabricatore, S., Braniecki, S., and Cairo, M.S. Trajectories of children’s health-related quality of life (HRQL) after myeloimmuno ablative conditioning (MAC) familial haploidentical (FHI) T-cell depleted (TCD) with T-cell addback stem cell transplantation (SCT) for poor risk sickle cell disease (SCD): Preliminary report from the FHI SCD consortium (IND14359). Presented, American Society of Blood and Marrow Transplantation, Feb 2017; Biology of Blood and Marrow Transplantation, March 2017; 23(3):S227-S228.
Braniecki, S., Talano, J-A., Moore, T.B., Weinberg, R., Keever-Taylor, C.A., Grossman, C., Baxter-Lowe, L.A., Parsons, S.K., Morris, E., Brand, P., Fabricatore, S., Ayello, J., Semidei-Pomales, M., van de Ven, C., Abikoff, C., Shenoy, S., McKinstry, R., and Cairo, M.S. Neurocognitive and neurological outcomes in children, adolescents and young adults with high-risk sickle cell disease (SCD) who have undergone familial haploidentical (FHI) allogeneic stem cell transplantation utilizing CD34 enrichment and T cell addback following myeloimmunoablative conditioning (MAC). Presented, American Society of Blood and Marrow Transplantation, Feb 2017; Biology of Blood and Marrow Transplantation, March 2017; 23(3):S:221-S222.
Ayello, J., Keever-Taylor, C., Weinberg, R., Grossman, B., Shenoy, S., Talano, J-A., Moore, T., Fabricatore, S., Semidei-Pomales, M., and Cairo, M.S. Processing of G-CSF mobilized peripheral blood stem cells (PBSC) from parental haploidentical sickle cell trait donors undergoing CD34 enrichment with T cell addback in children, adolescents and adults with high risk sickle cell disease (IND 14359). Oral presentation, AABB, October 2016.
PUBLICATIONS
Cairo, M.S., Talano, J., Moore, T.B., Shi, Q., Weinberg, R.S., Grossman, B., Shenoy, S. and the SCD Haplo Consortium. Familial haploidentical stem cell transplant in children and adolescents with high-risk sickle cell disease: A phase 2 clinical trial. Journal of the American Medical Association (JAMA) Pediatrics, Published online December 09, 2019. Doi:https://doi.org/10.1001/jamapediatrics.2019.4715; PMID: 31816036
*Highlighted Publications*
The ethics of a proposed study of hematopoietic stem cell transplant for children with "less severe" sickle cell disease.
Nickel RS, Hendrickson JE, Haight AE.
Abstract is available at pubmed.gov
For more information about the article, contact Robert.Nickel@choa.org
The ethics of a proposed study of hematopoietic stem cell transplant for children with "less severe" sickle cell disease.
Nickel RS, Hendrickson JE, Haight AE.
Abstract is available at pubmed.gov
For more information about the article, contact Robert.Nickel@choa.org
**Appeal to the President**
Andrea M. Williams , Founder & Executive Director of Children's Sickle Cell Foundation, submitted this letter to our nation's highest office requesting increased funding for sickle cell disease research.
Click here to read the letter.
Andrea M. Williams , Founder & Executive Director of Children's Sickle Cell Foundation, submitted this letter to our nation's highest office requesting increased funding for sickle cell disease research.
Click here to read the letter.